Hyderabad-based Reddy's Laboratories Ltd has announced that it has launched Sevelamer Carbonate Tablets, 800 mg,a therapeutic equivalent generic version of Renvela (sevelamer carbonate) Tablets, a trade mark of Genzyme Corporation, in the US Market
The drug was approved by the US Food and Drug Administration (USFDA), the pharmaceutical company said in statement here on Friday. "We are very pleased to bring Sevelamer Carbonate Tablets to market at this time," says AlokSonig, Executive Vice President and Head of the North America Generics business at Dr. Reddy's.
"This launch represents Dr. Reddy's expertise and commitment to provide affordable alternatives for complex, limited-competition products to market." This is the Company's eighth overall and fourth limited-competition launch this fiscal year. The Renvela® brand and generic had US sales of approximately 1.88 billion US dollars MAT for the most recent twelve months ending in July 2017 according to IMS Health, it said. Dr Reddy's Sevelamer Carbonate Tablets, 800 mg are available in the bottle count size of 270 tablets.